1/10
07:02 pm
halo
How Halozyme's ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How Halozyme's ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story [Yahoo! Finance]
1/10
03:36 am
halo
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains [Yahoo! Finance]
Low
Report
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains [Yahoo! Finance]
1/9
07:03 pm
halo
HALO or AXSM: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
HALO or AXSM: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
1/8
07:05 pm
halo
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® [Yahoo! Finance]
Low
Report
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® [Yahoo! Finance]
1/8
01:32 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a "buy" rating on the stock.
1/8
08:00 am
halo
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
Medium
Report
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
1/7
08:35 am
halo
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience [Yahoo! Finance]
Low
Report
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience [Yahoo! Finance]
1/5
07:13 am
halo
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity [Yahoo! Finance]
Low
Report
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity [Yahoo! Finance]
1/5
07:00 am
halo
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Low
Report
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
1/1
03:38 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 [Yahoo! Finance]
12/23
05:31 am
halo
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]
Low
Report
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]
12/23
03:32 am
halo
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
Low
Report
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
12/23
12:27 am
halo
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
Low
Report
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
12/22
09:34 am
halo
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]
Low
Report
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]
12/19
08:04 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
12/18
07:00 am
halo
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
Medium
Report
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
12/15
04:07 am
halo
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) [Seeking Alpha]
Low
Report
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) [Seeking Alpha]
12/8
04:05 pm
halo
Jim Lang Elected to Halozyme's Board of Directors
Low
Report
Jim Lang Elected to Halozyme's Board of Directors
12/4
02:53 pm
halo
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]
Low
Report
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]
12/4
01:42 pm
halo
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]
Low
Report
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]
12/4
01:26 pm
halo
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
Low
Report
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
12/4
08:43 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
12/2
03:45 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
11/28
07:02 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/28
02:23 am
halo
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term [Yahoo! Finance]
Medium
Report
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term [Yahoo! Finance]